Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
China’s November Economic Data Signals Slowing Industrial Output and Weak Consumer Demand 
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.
